Cleo Diagnostics has partnered with HcFocus, a New York healthcare consultancy, to penetrate the US market for its ovarian cancer blood test.

The collaboration focuses on securing regulatory approval via the Food and Drug Administration, conducting clinical trials, and engaging with insurers and the medical community.

Recent peer-reviewed publications validated the test's superior performance.

The partnership aims to expedite market entry and enhance early ovarian cancer diagnosis.